Skip To Main Content
Sung-Jin Hong on Muck Rack

Sung-Jin Hong

As seen in: American Journal of Cardiovascular Drugs, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, JAMA Cardiology, The Lancet, AHA/ASA Journals, JACC (Journal of the American College of Cardiology), Canadian Journal of Cardiology, International Journal of Cardiology, European Journal of Vascular and Endovascular Surgery
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sung-Jin

Contact Sung-Jin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk : A Systematic Review and Meta-Analysis

|
By Andrea Zito, Antonio Landi, Deepak L. Bhatt, Shao-Liang Chen, Giuseppe De Luca, Anna Franzone, Hyeon-Cheol Gwon, Jeehoon Kang, Joo-Yong Hahn, Sung-Jin Hong, Yangsoo Jang, Byeong-Keuk Kim, Hyo-Soo Kim, Takeshi Kimura, Roxana Mehran, Philippe Gabriel Steg, Gregg W. Stone, Pascal Vranckx, Stephan Windecker, Marco Valgimigli, Kyoung-Woo Park
| JAMA Cardiology
Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis Key Points Question Among patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI), is an abbreviated dual antiplatelet therapy (DAPT) regimen safer and as effective as standard DAPT duration?
Open in Who Shared Issue with article?

Geographical variations in the effectiveness and safety of abbreviated or standard antiplatelet therapy after PCI in patients at high bleeding risk

|
By Yonsei College, Pascal Vranckx, Jessa Ziekenhuis, Yukio Ozaki, Sung-Jin Hong, Dik Heg, Enrico Frigoli, Marie-Claude Morice, Bernard Chevalier, Yoshinobu Onuma, Stephan Windecker, Maurizio Di Biasi, Dariusz Dudek, Owen Raffel, Paolo Calabrò, Robert Whitbourn, Kiyokazu Shimizu
| Canadian Journal of Cardiology Verified
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Open in Who Shared View Duplicates (28) Issue with article?

Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial

|
By Byeong-Keuk Kim, Sung-Jin Hong, Seung-Jun Lee, Yongsung Suh
| AHA/ASA Journals
Background: Stopping aspirin within 1 month after implantation of a drug-eluting stent (DES) for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome (ACS). The aim of this study was to investigate whether ticagrelor monotherapy after <1 month of dual antiplatelet therapy (DAPT) is noninferior to 12 months of ticagrelor-based DAPT for adverse cardiovascular and bleeding events in patients with ACS.
Open in Who Shared Issue with article?
See all 14 licensed articles (15 Total)